Establishing Pheno- and Genotyping

• Conditions: F30-F39; Mood [affective] disorders

• Registration Number: DRKS00025396
• Lead Sponsor: Institut für Experimentelle und Klinische Pharmakologie, UKSH, Campus Kiel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Informed consent
• (Planned) use of at least one of the following antidepressants:
o citalopram
o sertraline
o venlafaxine
o paroxetine
o mirtazapine
• (Planned) assessment of Hamilton depression scores (HAM-D17)

Exclusion Criteria

• Not of legal age
• Non-compliance and other study-endangering factors as determined by the investigator

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Specificity, precision and limits of quantification of phenotyping<br>2. Concordance of multiple genotyping

Secondary Outcome Measures

Name	Time	Method
1. Concordance of the genetically predicted phenotype to the measured phenotype<br>2. Correlation of these phenotypes with the change in depth of depression (Hamilton score) and dose<br>3. Scatter of all target values for future case number planning<br>4. Frequency of prescribing of certain antidepressants and co-medication<br>5. Distribution of patients in the 9-field TDM table